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Studies have shown that fatty acids from fish and fish oils, like eicosapentaenoic acid (EPA) 
and docosapentaenoic acid (DHA) may have a beneficial role in cancer by inhibiting 
proliferation or inducing apoptosis of the cancer cells. Several mechanisms involving 
different metabolites (eicosanoids) of the fatty acids have been suggested for the anti-cancer 
actions, but the detailed effects are still not known. One of the eicosanoid groups of the fatty 
acids are epoxy-EPAs. Little have been investigated about epoxy-EPAs’ effect on cancer 
cells.  
This experiment is based on previous studies from this laboratory that have shown an anti-
proliferative effect of epoxy-EPA on murine endothelial cells (unpublished data). In this study 
the effect of 8,9-epoxy-EPA was tested on human breast cancer cell line MDA-MB-231. The 
epoxide was tested alone and in combination with an epoxide hydrolase inhibitor, N’N-
dicycyclohexylurea (DCU).  Different cell viability assays were assessed to investigate the 
effect of 8,9-epoxy-EPA on cancer cell proliferation. Cell cycle and immunoblotting were 
carried out to test if cell cycle regulatory proteins were affected.  8,9-epoxy-EPA was found to 
increase cell viability of MDA-MB-231. No change in cell cycle regulatory proteins was 
found.  
8,9-epoxy-EPA was also tested on the MDA-MB-231 cells together with a well known anti-
cancer drug, paclitaxel. Cell viability assay and cell cycle analysis were assessed. An increase 
in cell viability of cell treated with both 8,9-epoxy-EPA and paclitaxel compared to cell 
treated with paclitaxel alone was found. No effect of 8,9-epoxy-EPA on cell cycle was 
observed.  
Results from these experiments are not what we expected based on previous studies. Further 
studies on cell mechanism and apoptosis are required to investigate possible differences in 





























Cancer is a leading cause of death worldwide. In 2005 7.6 mill people died of cancer (13% of 
all deaths worldwide). The frequency of cancer increases with age, the range between 55 and 
75 years being the age where most cancer mortalities occur. The cancer types with the highest 
mortality rates are lung, stomach, liver, colon and breast cancer.  
About  1/3 of all cancer incidences could have been prevented by change of lifestyle (healthy 
diet, physical activity, less alcohol and tobacco) or by reduced exposure to cancer risks like 
chemicals, radiation and too much sunlight.  
A cancer tumor can be defined as an abnormal mass of tissue that grows uncoordinated and 
more rapidly that of the normal tissue. The uncontrolled, rapid growth happens as a result of 
some sort of stimulus. The cancer cell proliferation does not respond normal to the regulatory 
influences that control normal cell growth. 
A tumor is made up of two components, the parenchyma and the supporting, non-neoplastic 
cells. The latter part is made up of connective tissue and blood vessels. It supplies the 
parenchyma with nutrients via the blood stream and support the growth of the parenchyma 
cells. The parenchyma is made up of neoplastic cells. This part determines the tumors 
biological behavior.  
Cancer tumors arise from one single cell, and originate in genetic damage. This genetic 
damage can be initiated by environmental agents, such as chemicals, radiation or viruses. It 
can also be inherited. The transformation from a normal cell to a tumor cell is a multistage 
process. Replication of the DNA damaged cell can results in somatic cells with mutations in 
the genome. This mutation can result in activation of growth-promoting oncogenes, 
alterations of genes that regulate apoptosis or inactivation of cancer suppressor genes. This 
leads to expression of altered genes, loss of regulatory gene products and the development of 
a malign tumor.  
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Some of the changes in cell physiology that occurs in cancer tumors compared to normal 
tissue are self-sufficiency in growth signals, the cells do not respond to growth-inhibitory 
signals, respond to programmed cell death, sustained angiogenesis and gain the ability to 
invade and metastasize.  
Metastasis is when a cancer tumor spread and invades other parts of the body. Tumors can 
spread through seeding within body cavities, through the lymphatic system or the blood 
circulation [1, 2]. 
 
1.1.1 Cancer cell proliferation 
Proliferation is the growth or cell division of cells. The proliferation of cancer cells is often 
more rapidly and less controlled than normal cells. Stimulation of a normal cell into 
proliferation depends upon the external signals of growth factors. They bind to receptors on 
the cell surface which initiates a series of biochemical changes within the cell. This eventually 
leads to cell division. Tumor cells are not dependent on external growth factors in the same 
way as normal cells. They are able to proliferate when the concentration of growth factors are 
much lower than those required by normal cells. Tumor cells also may secrete their own 
growth factors and stimulate their own proliferation. When normal dividing cells reach a 
certain density they stop proliferating. Cancer cells continue to replicate to much higher 
densities than normal cells [3].  
 
1.1.2 Cell cycle 
An important mechanism that regulates proliferation is the cell cycle. After a growth stimulus, 
cells may enter the cell cycle in G1 phase, pass through S phase, in which DNA synthesis is 
stimulated, and progress to G2 phase ready for mitosis (M phase). This progression involves 
the concerted interplay of cyclin proteins, the cyclin-dependent kinases (CDKs), which are the 
catalytic subunits, and the CDK-inhibitors. The cyclins binds to CDKs and make complexes 
that are involved in activating of the essential substrates required for DNA synthesis and 
mitosis. Thus, cyclin-CDK complexes regulate progression through the cell cycle. Cyclin D 
regulates the cells progression from G0 (quiescent phase) to G1 phase. At the end of G1 phase 
and into S phase, cyclin E is expressed. From S phase to G2, cyclin A is the regulatory 
protein. And into M phase cyclin B regulatory proteins are expressed. CDK-inhibitors stops 
cell progression through the cell cycle. The relative levels of cyclins, CDKs and CDK-
inhibitors change throughout the cell cycle [4]. 
 
Figure 1.1: Cell cycle. The cells enter the cells cycle at G1 phase, DNA is replicated at S phase and cell division 
happens at M phase.  
Flow cytometry is a method used to measure the proportion of cells in each phase of the cell 
cycle. The DNA of the cells is stained with a fluorescent dye before they are sent in a fluid 
stream through a laser beam. The scatter and emitted fluorescence from each cell is measured 
and directed to detectors by an optic filter. The electric system converts the light signals to 
electronic signals that can be processed by a computer.  
It is cells size, granularity, internal complexion and fluorescence intensity that are measured. 
In cell cycle analysis the cells are sorted based on their DNA concentration. Cells in G1 phase 
have only one set of DNA, cells in G2 phase have two sets (double amount) and cells in S 
phase have something in between [5]. 
 
1.1.3 Angiogenesis 
Cancer tumors cannot enlarge to a size beyond 1-2 mm unless they are vascularized. The 





oxygen and nutrients can diffuse from blood vessels. Thus, angiogenesis is required for 
continued tumor growth. Angiogenesis is also required for metastasis through blood.  
Angiogenesis is induced by the tumor cells own production of angiogenic factors. Some of the 
most important angiogenic factors are vascular endothelial growth factor (VEGF) and 
fibroblast growth factor. When a tumor is subject to hypoxia, hypoxia-inducible factor-1 
(HIF-1) is released. HIF-1 controls transcription of VEGF. Thus, hypoxia can induce 
apoptosis [2].  
 
1.1.4  Breast cancer 
Breast cancer (cancer mammae) is the most frequent type of cancer among women. About 
502 000 people died of breast cancer worldwide in 2005. In Norway, 24488 new incidence of 
cancer were discovered in 2006. From these, 2673 incidences were breast cancer. There is no 
certain knowledge about the cause of breast cancer development, but heritage, gender and 
hormonal conditions are some of the risk factors.  
There are different types of breast cancers. Some have rapidly growing tumors which 
metastasize early in the development. Others have slowly growing tumors that do not 
metastasize at all. A large proportion of breast cancers are estrogen dependent. These tumors 
express estrogen receptors which is an important target in the treatment of this type of breast 
cancer. 
The prognosis for breast cancer is good when it is detected at an early stage and treated 
according to best evidence. The aim for treatment of breast cancer without metastases is 
curative. For breast tumors with metastasis there still is no curative treatment. In this case 
palliative care and keeping the development of the cancer to a minimum is the aim of the 
treatment [1, 6-8].  
In this experiment the human breast cancer cell line MDA-MB-231 was used. MDA-MB-231 
cells are estrogen independent epithelial cells. The cells express epithelial growth factor 
receptors. They are aggressive and rapidly growing. [9] 
 
 
1.1.5 Anti-cancer drug paclitaxel 
Paclitaxel is a complex diterpene derived from Taxus brevifolia or by synthesis. It belongs to 
the taxane group.  It has anti-tumor activity against ovarian, breast, lung and prostate cancer. 
It acts by binding to β-tubulin and promote the formation of highly stable microtubules that 
resist depolymerization. This results in preventing normal cell division and cell cycle arrest in 
G2/M phase. Some of the most sever adverse effects are bone marrow depression and 
peripheral neuropathy. Paclitaxel is thought to be metabolized in the liver. Docetaxel is 
another taxane anti-cancer agent that is related to paclitaxel [10, 11].  
 
1.2 n-3 and n-6 polyunsaturated fatty acids 
Fatty acids are carboxylic acids containing long unbranched carbon chains. The chains can be 
either saturated (containing no double bonds) or unsaturated (containing one or more double 
bonds) and vary in length. Omega-3 (n-3) and omega-6 (n-6) fatty acids are families of 
polyunsaturated fatty acids (PUFA), which have more than one double bond. They are 
numbered according to the location of the double bond closest to the terminal methyl carbon.  
 
Figure 1.2: The n-3 fatty acid eicosapentaenoic acid and the n-6 fatty acid arachidonic acid. The double bond 
closest to the terminal methyl carbon starts at n-3 and n-6, respectively. 
n-3 and n-6 PUFAs are essential fatty acids (EFA). The human body does not contain the 
enzymes necessary to synthesize the n-3 and n-6 double bonds; therefore they have to be 
obtained through the diet. n-3 and n-6 PUFAs are components of fish and fish oils, plant oils 
and animal tissue. n-3 PUFAs are the predominant fatty acids in fish and fish oil, and n-6 in 





n-3 PUFAs are synthesized from α-linolenic acid (18:3). Through desaturase and elongation 
enzymes n-3 PUFAs like eicosapentaenoic acid (20:5) and docosahexaenoic acid (22:6) are 
formed. The rate of conversion from α-linolenic acid to longer-chain metabolites in humans is 
very low, suggesting that a high proportion of the latter must come from the diet [12]. n-6 
fatty acids are synthesized from linoleic acid (18:2). This n-6 fatty acid is a precursor for γ-
linolenic acid (18:3) and arachidonic acid (20:4). 
 
1.2.1 Eicosanoids of n-3 and n-6 polyunsaturated fatty acids 
Eicosapentaenoic acid (EPA) and arachidonic acid (AA) are analogue fatty acids from the n-3 
and n-6 families, respectively. In the body EPA and AA are incorporated into membrane 
phospholipids. They may subsequently be released from phospholipids and metabolized by 
cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP 450) enzymes to a 
range of different eicosanoids. COX metabolism leads to the formation of prostaglandins and 
thromboxanes, LOX leads to the formation of leukotrienes and CYP 450 hydroxylates or 
epoxidises the double bonds to make hydroxy- and epoxy-PUFAs. 
 
1.2.2 Epoxy-PUFA is formed by CYP 450 metabolism 
Both AA and EPA are metabolized through CYP 450. Some of the metabolites derived are 
monoepoxides. The epoxides is formed between all of the possible C=C double bonds of the 
fatty acid chain [13, 14]. The formation is mediated by several CYP 450 isoenzymes. AA is 
converted to 14,15-EET by CYP 2E1, 2J2 and 1A1, to 11,12-EET by CYP 2C8, 1A1 and 1A2 
and to 8,9-EET by CYP 2C19, 2C18 and 3A4. EPA is converted to 17,18-epoxy-EPA by 
CYP 2D6, 1A2 and 1A1, 14,15-epoxy-EPA is formed by CYP 2C8 and 2C9, 11,12-epoxy-
EPA is formed by CYP 2C9 and 2C18 and 8,9-epoxy-EPA is formed through CYP 2C9 and 
2C19 [13].  The conversion from fatty acid to epoxide is also catalyzed by other CYP 450 
isoenzymes [13].  
 
1.3 Epoxide hydration to diols is mediated by the soluble epoxide hydrolase 
Studies have shown that the epoxide formed when PUFAs are metabolized by CYP 450 may 
be rapidly hydrated to diols by epoxide hydrolase (EH) [13]. There are two types of epoxide 
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hydrolases, soluble epoxide hydrolase (sEH) present in the cytotsol and microsomal epoxide 
hydrolase. sEH has been shown to be the most efficient of the two [15]. Inhibition of sEH can 
prevent the epoxide from being hydrated to the diol. N’N-dicyclohexylurea (DCU) is an 
epoxide hydrolase inhibitor that has been shown to inhibit sEH effectively [16]. 
 
1.4 Effect of PUFA on cancer 
The effects of polyunsaturated fatty acids on a range of cancer types, including breast cancer, 
have been tested in several studies, both epidemiological and experimental. The results have 
been somewhat inconsistent. Evidence from in vitro and animal studies of n-3 PUFA indicates 
that these fatty acids can slow down or inhibit cancer cell proliferation [17-21]. 
Epidemiological studies of n-3 fatty acids and cancer risk have not been able to show the 
same result. The conclusion among the latter is often that there is no significant reduction in 
cancer risk [22-24]. However, although the results are not significant there are trends that 
indicate beneficial effects of n-3 fatty acids on cancer development [22, 24]. Possible reasons 
for this inconsistency between epidemiological studies and animal and in vitro experiments 
could be epidemiological methodology issues such as sample size, adjustment for potentially 
confounding variables or detail and quality of the diet follow up. The laboratory models used 
in animal and in vitro experiment are not easily extrapolated to living humans, and there also 
might be a higher level of PUFA exposure to cancer cells in animal and in vitro models. 
Some studies have investigated the effect of n-3 fatty acids versus n-6 fatty acids on cancer 
risk. They have found that an increased consumption or tissue ratio of  n-3 fatty acids versus 
n-6 fatty acid  may decrease the risk of developing cancer [25-29]. 
Although epidemiological studies and some experimental studies support a beneficial effect of 
n-3 diets on breast cancer the mechanism and detailed effects are unknown. 
The effect of n-3 fatty acids on growth of the breast cancer cell line MDA-MB-231  have been 
investigated in several studies [17, 18, 20, 21]. Studies usually report a decrease in cell 
proliferation when MDA-MB-231 cells are exposed to n-3 fatty acids [17, 18, 20, 21]. Some 
differences have been found regarding the growth inhibiting effect of EPA and DHA. DHA 




1.5 Effect of epoxy-PUFA on cell proliferation 
The monoepoxidized forms of arachidonic acid (EETs) have been found to promote the 
proliferation of endothelial [30, 31] and cancer cells [32]. The mechanism is not fully 
understood, but it has emerged that EETs protect cells from death pathways (apoptosis) [31, 
32] and stimulate the growth of new blood vessels (angiogenesis) [30]. Angiogenesis could 
stimulate cancer growth by increasing the supply of nutrients via the blood stream. In 
contrast, little is known about the effect of monoepoxidized n-3 fatty acids on cell growth. 
 
1.6 Mechanisms for n-3 fatty acid inhibition of cancer cell proliferation.  
Several mechanisms for how n-3 fatty acids inhibit cancer proliferation have been suggested. 
The most prominent one might be n-3 fatty acid inhibition of the formation of AA derived 
eicosanoids [33, 34]. High amounts of ingested n-3 fatty acids could replace n-6 fatty acids in 
membrane phospholipids [35].  This may result in a decreased level of n-6 fatty acid derived 
products, such as prostaglandin E2 (PGE2) because of the increased supply of n-3 substrates 
[34].  
PGE2 is formed through COX metabolism of n-6 fatty acids [33]. COX enzymes are found to 
be over expressed in some tumors [36]. In addition, PGE2 induces the production of COX-2 
mRNA, which further increases the production of PGs [34]. Studies have shown that PGE2 is 
important for cancer growth [33, 34, 37], possibly by protecting the cancer cells against 
apoptosis [38].  Metabolism of n-3 fatty acids by COX produces prostaglandin E3 (PGE3) 
[33]. PGE3 have been found to inhibit cancer cell growth [33], but the mechanism is not clear. 
PGE3 have also been found to be less potent in inducing the production of COX-2 mRNA 
compared to n-6 fatty acids [34]. This means that a higher level of n-3 fatty acids than n-6 
fatty acids may reduce the induction of COX-2 and further, the amount of n-6 fatty acid 
eicosanoids.  
These findings indicate that a higher level of n-3 fatty acids could modulate the n-6 fatty acid 
metabolism, membrane phospholipid incorporation of n-6 fatty acids and induction of COX 
by n-6 fatty acids. This may decrease the amount of n-6 fatty acid derived eicosanoids, 
resulting in a decreased cancer cell proliferation. Importantly, EPA has also been found to 
compete with AA for binding to CYP 450 enzymes [13]. 
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n-6 EETs have been shown to stimulate cell proliferation by increasing cyclin D1 expression 
[39]. In recent study previously done in this laboratory, it has been found that epoxides of the 
n-3 EPA decrease cyclin D1 expression in murine endothelial cells (unpublished data). 
Whether the same process occurs in breast cancer cell lines has not yet been tested, and is a 
subject of this project. 
As mention previously, an alternate mechanism for decreasing tumor growth is via inhibition 
of angiogenesis. A relationship might exist between COX-2 activity and angiogenesis in 
cancer cells [40]. Indeed, a recent study from this laboratory has investigated n-3 derived PG 
metabolites formed by COX on angiogenic processes in tumor cells [41]. Thus, COX-derived 
PGs from n-6 fatty acids stimulated angiogenesis whereas n-3 PGs did not. 
Nuclear factor κB (NFκB) is a protein complex that regulates genes that control cell 
proliferation and cell survival. NFκB proteins are present as inactive forms in the cytoplasm 
in normal cells. They are bound to inhibitory proteins termed IκBs [42, 43]. Aberrant nuclear 
expression of NFκB has been found in breast cancer cells [42]. Inhibition of NFκB in breast 
cancer cells leads to apoptosis [42]. When IκB is phosphorylated, NFκB becomes free and can 
move towards the nucleus and initiate transcription of various genes. n-3 fatty acids decrease 
the amount of phosphorylated IκB [43]. The role of n-3 and n-6 derived eicosanoids formed 
by COX and CYP 450 enzymes in regulation of NKκB have not yet been assessed. 
The mechanisms for n-3 fatty acid inhibition of cancer cell growth are not completely clear. 
However, it seems likely that the inhibition is a composite of several potential mechanisms.  
 
1.7 Effect of anticancer drugs in combination with n-3 fatty acids 
Studies have shown a decrease in cell viability when cancer cells are exposed to cytotoxic 
anticancer drugs in combination with n-3 PUFA, by comparison with the anticancer drug 
alone [44-46]. One study found that EPA decreased the dose of paclitaxel required to kill 50% 
of breast-tumor-derived MDA-MB-231 cells in culture (EPA reduced the IC50 of paclitaxel 
with 45%) [45].  Docosahexaenoic acid (DHA) also decreases MDA-MB-231 cell growth in 
combination with anticancer drugs paclitaxel and docetaxel [44]. A third study found a 
decrease in MDA-MB-231, but not in the alternate breast cancer cell line MCF-7, after 
exposure to DHA in combination with doxorubicin [46]. It has also been successful studies of 
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a combination drug of DHA and paclitaxel. When these are taken together, the required dose 
of paclitaxel and the toxicity that follows the treatment are both reduced [47]. 
Some of the suggested mechanisms for the enhanced cytotoxicity of anticancer drugs when 
combined with n-3 fatty acids are increased membrane fluidity due to the higher  
incorporation of n-3 PUFAs [48] or the involvement of lipid peroxidation [49]. 
 
1.8 The purpose of the study 
The purpose of this study was to investigate the effect of epoxy-EPA on cancer cell growth. 
Little is known about the effect of the CYP 450 derived epoxy-EPAs and their role in cancer 
cell proliferation. MDA-MB-231 breast cancer cells where treated with 8,9-epoxy-EPA, alone 
and in combination with N’N-dicyclohexylurea (DCU), an epoxide hydrolase inhibitor. In 
further studies, MDA-MB-231 were also exposed to a combination of 8,9-epoxy-EPA and the 
well known anticancer drug paclitaxel, in order to investigate any synergistic or additive 
effects. Flow cytometry and Western blot analysis of cell cycle proteins was undertaken to 
investigate the impact of these treatments on cell growth and proliferation. Important 













2. Materials and methods 
 
2.1 Materials 
2.1.1 Chemicals used in cell culture and experiments 
Chemical Purchased from 
8,9-epoxy-EPA Was kindly donated from Dr. Sarah Cui 
Acrylamide/bis, 40% Amresco (Solon, Ohio, USA) 
Ammonuim persulfat (APS) Univar, Ajax Chemicals, (Sydney, Australia) 
Anti-β-actin IgG Santa Cruz biotechnology (Santa Cruz, CA, 
USA) 
Anti-cdk4 IgG Santa Cruz biotechnology (Santa Cruz, CA, 
USA) 
Ant-cdk6 IgG Santa Cruz biotechnology (Santa Cruz, CA, 
USA) 
Anti-cyclin D1 IgG Santa Cruz biotechnology (Santa Cruz, CA, 
USA) 
Anti-cyclin E IgG Santa Cruz biotechnology (Santa Cruz, CA, 
USA) 
Anti-p21 IgG Santa Cruz biotechnology (Santa Cruz, CA, 
USA) 
Anti-mouse IgG Santa Cruz biotechnology (Santa Cruz, CA, 
USA) 
Anti-rabbit IgG Santa Cruz biotechnology (Santa Cruz, CA, 
USA) 
Aprotinin Sigma Chemical Company (St. Louis, MO, 
USA) 
BCA Protein Assay Reagent kit Pierce (Rockford, Illinois, USA) 
Dicyclohexylurea (DCU) Sigma Chemical Company (St. Louis, MO, 
USA) 




Diploma skim milk powder Diploma, Australia 
Dithiothreitol (DTT) Sigma Chemical Company (St. Louis, MO, 
USA) 
Dulbecco’s modified eagle medium 
(DMEM) 
Thermo Fisher Scientific (Waltham, MA, 
USA) 
Fetal bovine serum (FBS) Thermo Fisher Scientific (Waltham, MA, 
USA) 
Glycine Amresco (Solon, Ohio, USA) 
N-(2-hydroxlethyl)piperazine-N’(2-
ethanesulfonic acid) ( HEPES) 
USB Corporation (Cleveland, OH, USA) 
Leupeptin Sigma Chemical Company (St. Louis, MO, 
USA) 
L-glutamine Thermo Fisher Scientific (Waltham, MA, 
USA) 
Nonidet P40 (Igepal) Sigma Chemical Company (St. Louis, MO, 
USA) 
Paclitaxel Sigma Chemical Company (St. Louis, MO, 
USA) 
Penicillin/Streptomycin Thermo Fisher Scientific (Waltham, MA, 
USA) 
Phenyl metyl sulfonyl fluoride (PMSF) Sigma Chemical Company (St. Louis, MO, 
USA) 
Phosphate buffer saline (PBS) tablets Amresco (Solon, Ohio, USA) 
Ponseau S red stain ICN biomedical (Solon, Ohio, USA) 
Prestained protein molecular weight marker Fermentas (Canada) 
Propidium iodide (PI) Sigma Chemical Company (St. Louis, MO, 
USA) 
Ribonuclease A (Rnase A)  Sigma Chemical Company (St. Louis, MO, 
USA) 
Sodium deoxycholate Sigma Chemical Company (St. Louis, MO, 
USA) 




Sodium lauryl sulphate (SDS) A.G. Scientific inc (San Diego, CA, USA) 
TEMED Amresco (Solon, Ohio, USA) 
Thiazolyl blue tetrazolium bromide (MTT) Sigma Chemical Company (St. Louis, MO, 
USA) 
Tris Amresco (Solon, Ohio, USA) 
Trypan blue stain Invitrogen (Mount Waverly, VIC, Australia) 
Trypsin/EDTA Thermo Fisher Scientific (Waltham, MA, 
USA) 
Tween-20  Amresco (Solon, Ohio, USA) 
 
 
2.1.2  Solutions for cell culture 
Plain media, 900ml 
DMEM 9.87 g 
Sodium hydrogencarbonate 1.2 g 
HEPES 5.21 g 
NaOH Adjust pH to exactly 7.2 
Baxter sterile water 900 ml 
Mix on magnetic stirrer. Filter sterilize in tissue culture hood using VacuCap60 0.2µm. Store 
at 4⁰C. 
Complete media (10% FBS), 255ml 
Plain media 225 ml 
FBS 25 ml 
L-glutamine 2.5 ml 
Penicillin/streptomycin mix 2.5 ml 





0.5% FBS media, 255ml 
Plain media 225 ml 
FBS 1.125 ml 
L-glutamine 2.5 ml 
Penicillin/streptomycin mix 2.5 ml 
 
Phosphate buffered saline (PBS), pH 7.4, tissue culture grade 
PBS tablet 1 
Baxter sterile water 100ml 
Dissolve and sterilize at 121⁰C for 20 min in autoclave. Store at 4⁰C. 
 
2.1.3 Buffers for flow cytometry 
Incubation buffer, 10ml 
0.1M PBS 9.8 ml 
10% Nonidet P40 (Igepal) 0.1 ml 
10 mg/ml Rnase A 0.1 ml 
Make on the day. 
 
2.1.4 Buffers and solutions for Western blot analysis 
Tris pH 8.8, 100ml 
Tris 18.15g 
Deionized water Make up to 100ml 
HCl Adjust pH to 8.8 







Tris pH6.8, 100ml 
Tris 6.0g 
Deionized water Make up to 100ml 
HCl Adjust pH to 6.8 
Store at 4⁰C. 
 
Sample buffer, 90ml 
Tris pH 6.8, 1M 25.0ml 
Glycerol 23.0ml 
SDS 10% 40.0ml 
Bromophenol blue 0.1% 2.0ml 
Deionized water Make up to 90ml 
Aliquot into 4.5ml. Add 0.5ml 0.5M dithiothereitol before use. Store at -20⁰C. 
 
5 x running buffer, pH 8.3, 1L 
Tris 15.0 g 
Glycine 72.0 g 
SDS, 10% 50 ml 
Deionized water Make up to 1L 
Store at 4⁰C. 
1 x running buffer: 100ml 5 x running buffer + 400ml deionized water. 
 
Transfer buffer, 2L 
Tris 6.06 g 
Glycine 28.8 g 
Methanol 400 ml 
Deionized water Make up to 2L 
Store at 4⁰C. 
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10 x TBS stock, pH 7.4, 2L 
Tris 121.0 g 
NaCl 233.8 g 
Deionized water Make up to 2L 
HCL Adjust pH to 7.4 
Store at 4⁰C. 
1 x TBS: 100ml 10 x TBS + 900ml deionized water 
1 x TBS/Tween, 1L 
10 x TBS stock 100 ml 
Deionized water 900 ml 
Tween-20 (0.05%) 0.5 ml 
Mix on magnetic stirrer. Store at room temperature. 
 
Blocking milk solution, 5%, 100ml 
Diploma skim milk 5.0 g 
1 x TBS/Tween 100 ml 
Mix on magnetic stirrer.  
 
2.1.5 Gels for Western blot analysis 
12% separating gel, 30 ml 
Deionized water 11.4 ml 
Acrylamide/bis, 40% 9 ml 
TrisHCL pH 8.8, 2.5M 9 ml 
SDS, 10% 300 µl 
Ammonium persulphate, 10% 300 µl 





5% stacking gel, 16 ml 
Deionized water 9.8 ml 
Acrylamide/bis, 40% 2 ml 
TrisHCL pH 6.8, 1.0M 4 ml 
SDS, 10% 160 µl 
Ammonium persulphate, 10% 80 µl 




Allegra 6R Centrifuge Beckman 
Altra 20 soft Imaging system CKx41 Olympus 
Biorad GS-800 Calibrated Densitomenter Biorad 
Coulter flow cytometer Beckman 
Email Air Handling Biological Safety 
cabinet, class II 
Email 
Eppendorf Centrifuge 5417 R Crown Scientific 
Odyssey LI-COR 
Olympus CKx41 Olympus 




2.2.1 Cell culture 
The MDA-MB-231 breast cancer cells line were kindly donated by Dr Nenad Petrovic of this 
laboratory. MDA-MB-231 is an epithelial breast cancer cell line isolated from the mammary 
gland of a 51-years old female caucasian. It is estrogen independent, aggressive and rapidly 
growing [9].  
The MDA-MB-231 cells were cultured in Dulbecco’s modified Eagle medium (DMEM), 
supplemented with 100units/ml penicillin, 100µg/ml streptomycin, 1% L-glutamine and 10% 
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fetal bovine serum (FBS). The cell were maintained in monolayer in T75 flasks, and 
incubated in 37⁰C in an atmosphere of 95% air and 5% CO2. All cell work was carried out in 
a tissue culture hood (Email Air Handling Biological Safety cabinet, class II), using only 
sterile equipment in direct contact with the cells. 
 
2.2.2 Passaging of MDA-MB-231 cells 
The MDA-MB-231 cells were passaged every 3rd or 4th day (when they had reached 90-100% 
confluence). Media was removed by aspiration using sterile Pasteur pipette and a vacuum 
line. 10mL phosphate buffered saline (PBS) was added to the opposite side of where the cells 
were attached. The flask was gently rocked about 5 times to wash away media residues from 
the cells. PBS was removed by aspiration. 2mL trypsin/EDTA (1:250 w/o phenol red) was 
added directly to the cells and the flask was incubated for 5 min in 37⁰C, 5% CO2. Cells were 
detached by gently tapping the flask. 10mL DMEM was added to the flask. Cells were 
suspended in the media, transferred to a 15mL tube and centrifuged at 1250 rpm in 5 min 
(Allegra 6R Centrifuge). Supernatant was removed by aspiration and the cell pellet was 
“flipped” to separate the cells. The cells were resuspended in 12mL DMEM and passaged into 
three T75 flasks containing 25mL DMEM each.  
 
2.2.3 Thawing of MDA-MB-231 cells 
Cells were kept in liquid nitrogen in cryotubes. Tubes were removed from the liquid nitrogen 
tank and into a 37⁰C water bath for about 30-60sec. The cells were transferred to a 15mL tube 
using 10mL heated DMEM and centrifuged at 1250 rpm for 5 min (Allegra 6R Centrifuge). 
Media was removed by aspiration and the cell pellet was “flipped” and resuspended in 10mL 
DMEM before transferred to a T75 flask containing 25mL DMEM. 
 
2.2.4 Seeding of MDA-MB-231 cells 
For experiments MDA-MB-231 were seeded in 24-well plates, 1mL in each well at a density 
of 1x105cells/ml. Media from one T75 flask was removed by aspiration. The cells were 
washed with PBS and incubated with trypsin/EDTA in 37⁰C, 5% CO2 for 5 min. After 
detaching, the cells were suspended in 10mL media, transferred to a 15mL tube and 
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centrifuged at 1250 rpm for 5 min (Allegra 6R Centrifuge). The supernatant was removed, the 
cell pellet “flipped” and resuspended in 12mL media.  Cell number was determined by cell 
counting using a hemacytometer (without trypan blue). The amount of cell suspension to 
make a 1x105cells/ml dilution in media was calculated.  Cells were seeded in 24-well plate, 
1ml cell suspension in each well. 
 
2.2.5 Harvesting of MDA-MB-231 cells 
Media was removed by aspiration using sterile Pasteur pipette and vacuum line. 1ml PBS was 
added to each well and the plate was rocked gently to wash out media residues. PBS was 
removed by aspiration. 200µl trypsin/EDTA was added to each well, and the plate was 
incubated in 37⁰C, 5% CO2 for 10 min. 0.5ml media containing 10% FBS was added to each 
well. Cells from each well were transferred to eppendorf tubes. Another 0.5 media was added 
to each well and transferred to the same tubes to make sure all the cells were harvested.  The 
tubes were centrifuged at 1250 rpm 5-10 min (Eppendorf Centrifuge 5417 R). Supernatant 
was removed.  
• For cell count: 
Cell pellets were resuspended in 0.5ml media.  
• For flow cytometry: 
Cell pellets were resuspended in 0.5ml ice-cold PBS and centrifuged at max speed at 4 ⁰C for 
5 min. PBS was removed; cell pellets were “flipped” and another 0.5ml ice-cold PBS was 
added. Cells were then centrifuged at max speed at 4⁰C for 5 min. PBS was removed and cell 
pellets were resuspended in ice-cold 80% ethanol and transferred to -20⁰C for at least one 
hour. 
• For western blotting: 
Cell pellets were harvested into 10ml tubes (several wells containing cells that had received 
the same treatment into the same tube to obtain sufficient protein for the analysis). After 




2.2.6 Experiments using MDA-MB-231  
For cell experiments, MDA-MB-231 cells were seeded in DMEM supplemented as described 
above. After 24 hr, the media was changed to DMEM containing the same amount of 
penicillin, streptomycin and L-glutamate, but with only 0.5% FBS. Old media was removed 
by aspiration, and immediately replaced with new media.  After another 24 hr, media was 
replaced with treatment media. Treatment media contained DMEM, same amount of 
penicillin, streptomycin and L-glutamate, 0.5% FBS and the different treatments.  Constant 
concentrations of 8,9-epoxy-EPA and DCU were used for all experiments (10µM). Because 
8,9-epoxy-EPA is dissolved in DMSO, cells treated with only DMSO were used as controls. 
Paclitaxel was used at three different concentrations, 2nM, 5nM and 10nM.  
 
2.2.7 Cell count and cell viability experiments on MDA-MB-231 cells 
 
Cell count using hemacytometer 
A hemacytometer is a graduated counting chamber that can be viewed under a microscope to 
determine the concentration of cells in a suspension. The central area of the instrument is 
defined by a set of grooves that form an “H” shape. Two counting areas with ruled grids are 
separated by the horizontal groove of the “H”. In each counting area there are 9 squares (1.0 
mm x 1.0 mm each). A glass coverslip is held at 0.1 mm above the surface of the counting 
area. Approximately 10µL of cell suspension is required to fill the counting chambers on each 
side [50]. 
In our experiments, the middle square in each counting chamber was counted.   
Cell count with trypan blue 
Trypan blue is a dye used to determine viable vs. non-viable cells. The dye is excluded from 
viable cells. Non-viable cells are colored dark blue.  
Cell suspension was diluted 1:1 with trypan blue and pipetted up and down several times to 
ensure a uniform suspension. The suspension was loaded into both counting chambers of the 
hemacytometer, and the number of viable cells was counted by microscopy at 100x 
magnification. Cells in one square of each counting chamber were counted. 
33 
 
Number of cell/ml = [(total number of cells counted/number of squares counted) x 
104cells/ml] / typan blue dilution 
Cell count without trypan blue 
This method was used for determining cell/ml in cell suspension when cells were seeded.  
Cell suspension was loaded to each side of the hemacytometer, and cells in one square at each 
counting chamber were counted. 
Number of cells/ml = (total number of cells counted/number of squares counted) x 104cells/ml 
MTT-assay 
MTT-assay is based on the cellular conversion of the tetrazolium salt, thiazolyl blue 
tetrazolium bromide (MTT), into a formazan product that is readily detected using a 96-well 
plate reader. The conversion is only carried out by viable cells. The absorbance is measured at 
540nm and is directly proportional to the number of live cells [51]. 
2.5mg/ml MTT-solution was added to each well and incubated in 37⁰C, 5% CO2 for 2 hr. 
Media was removed by aspiration.  The cells were dissolved in 200µl DMSO and shaken on 
an orbital shaker for 30 min. (Plates were covered with aluminum foil to protect the crystals 
from light). 100ul or 50ul of solutions were transferred to 96-well plates and read in a Victor3 
Wallac 1420 multilabel counter at 540nm. 
 
2.2.8 Cell cycle analysis of MDA-MB-231 cells using flow cytometry 
Flow cytometry measures the amount of DNA in cells. The cells flow in a fluid stream 
through a laser beam. Light scatter and fluorescence is measured and converted to electronic 
signals that are processed by a computer.  By measuring the amount of DNA, the test is able 
to identify the proportions of cells in different parts of the cell cycle [5].  
MDA-MB-231 cell pellets were fixed in 80% ethanol stored at -20⁰C for at least an hour and 
were then centrifuged at 2500 rpm at 4⁰C for 15 min (Eppendorf Centrifuge 5417 R). The 
ethanol was removed and the cell pellets were suspended in 0.5ml incubation buffer.  12.5µl 
2mg/ml propidium iodide (PI) was added to each tube before they were incubated on ice for 1 




2.2.9 Western blot analysis of MDA-MB-231 cells 
Western blot analysis is used to detect specific proteins in a sample. The proteins are 
separated by gel electrophoresis and then transferred electrophoretically to a nitrocellulose 
membrane. Antibodies are used to detect the specific proteins that are immobilized on the 
membranes. 
MDA-MB-2312 cell pellets were lysed using lysis buffer and the amount of protein in the 
lysate was quantified using Bicinhoninic acid- assay (BCA-assay), (see Appendix). The 
amount of lysate containing the required amount of protein was diluted 1:1 with sample buffer 
and water. Samples were loaded onto 1.5mm 12% SDS polyacrylamide gels. Gels were run at 
200V for about 2 hrs in 1 x running buffer. Proteins were transferred from the gel to 
nitrocellulose membranes (run at 100V for 1.5 hr in transfer buffer). 
Development of blot: 
The membranes were shaken in ponceau S dye on orbital shaker for 10 min and scanned to 
ensure efficiency of transfer.  The membranes were shaken in blocking milk solution on an 
orbital shaker for 1 hr before removal to blocking milk solution containing primary antibodies 
and incubation at -4⁰C on an orbital shaker overnight. Primary antibodies were removed by 
washing in TBS/Tween before incubating membranes in blocking milk solution containing 
secondary antibodies on an orbital shaker for 1 hr.  Secondary antibody was removed by 
washing in TBS/Tween and TBS only. Membranes were scanned using Odyssey (LI-COR) 









Tabel 2.1: Antibody dilutions used in western blotting. 
Antibodies 
Primary antibodies Dilutions 
β-actin 1:500 
Cyclin D1 1.500 
Cyclin E 1:500 
Cdk 4 1:500 






2.3 Statistic analysis 













3.1 Effect of FBS supplement and seeding density on growth of MDA-MB-231 cells. 
In preliminary experiments the growth conditions of MDA-MB-231 cells were optimized. 
Cells were seeded in 24-well plates at densities of 1x105cell/ml, 2x105cells/ml and 
3x105cells/ml and were cultured in DMEM media supplemented with 10%, 2% or 0% FBS. 
After 48 hr, MDA-MB-231 cells seeded at an initial density of 1x105cells/ml were about 
100% confluent when grown in 10% or 2% FBS DMEM. For cells seeded at the same 
density, but grown in the absence of FBS, a somewhat lower confluence was observed. Cells 
that were seeded at densities of 2x105cells/ml and 3x105cells/ml were fully confluent at the 
same time point, and a large proportion of dead cells were observed.  
 
Figure3.2: Effect of FBS supplement and seeding density on growth of MDA-MB-231 cells after 24 hr. 
In further experiments growth conditions in cultured MDA-MB-231 cells were assessed. Cells 
seeded in 24-well plates at densities of 0.7x105cells/ml and 1x105cells/ml were grown in 10%, 
0.5% and 0% FBS supplemented DMEM. The cells were cultured for 72 hr and MTT assays 
were conducted at 24 hr intervals. Figure 3.2 A shows that the increase in viability (MTT 
assay) for cells seeded at densities of 0.7x105 cells/ml after 24 hr was 66% (10% FBS), 39% 
(0.5% FBS) and 44% (0% FBS) compared to the 0 hr timepoint.  At 48 hr the cell viability 
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further increased to 167% (10% FBS), 119% (0.5% FBS) and 105% (0% FBS) over the 0 hr 
timepoint. From 48-72 hr the viability of cells grown in 0.5% and 0% FBS supplemented 
DMEM was reduced to, 108% and 77% respectively, compared to control. In contrast cell 
proliferation in 10% FBS DMEM was increased further by 343% over control.  The viability 
of cells seeded at 1x105cell/ml increased 71% (10% FBS), 42% (0.5% FBS) and 52% (0% 
FBS) after the first 24 hr (figure 3.2 B). At 48 hr further increases to 162% (10% FBS), 121% 
(0.5% FBS) and 72% (0% FBS) of control were noted. Between 48-72 hr cell proliferation 
was decreased for cells grown in 0.5% and 0% FBS to 132% and 50% of control (0 hr) 
respectively. Cells that were cultured in 10% FBS supplemented DMEM exhibited increased 
viability of 278% compared to 0 hr.   
 
 
Figure 3.2: MDA-MB-231 cells were seeded in 24-well plates at densities of 0.7x105cells/ml (A) and 
1x105cells/ml (B), were cultured in 10%, 0.5% and 0% FBS supplemented DMEM. Cell viability in 0.5% and 
0% FBS supplemented media decreased after 48 hr. A: At 24 hr the percentage increase of viable cells compared 
to 0 hr was 66% (10% FBS), 39% (0.5% FBS) and 44% (0% FBS), at 48 hr 167% (10% FBS), 119% (0.5% 
FBS) and 105% (0% FBS) and at 72 hr 343% (10% FBS), 108% (0.5% FBS) and 77% (0% FBS).  B: At 24 hr 
the percentage increases of viable cells compared to 0 hr were 71% (10% FBS), 42% (0.5% FBS) and 52% (0% 
FBS), at 48 hr 162% (10% FBS), 121% (0.5% FBS) and 72% (0% FBS) and at 72 hr 278% (10% FBS), 132% 





To avoid excessive stimulation of cell growth by FBS, the lowest possible serum 
concentration that maintained cell growth was selected for subsequent experiments. A density 
of 1x105 cells/ml seeded in 24-well plates and cultured in 0.5% FBS supplemented DMEM 
was used in most of our experiments. 
 
 3.2 Effect of 8,9-epoxy-EPA on MDA-MB-231 cell proliferation 
The effects of 8,9-epoxy-EPA (10µM) on MDA-MB-231 cells were assessed directly and in 
combination with the epoxide hydrolase inhibitor N,N’-dicyclohexylurea (10µM) for 24 hr. 
These conditions had been shown to be optimal in murine endothelial cell lines, and were 
adopted for the present experiment in human breast cancer cells. Cells treated with DMSO 
(vehicle control) and DCU alone were used as controls for 8,9-epoxy-EPA treated cells and 
8,9-epoxy-EPA+DCU treated cells, respectively. 
 
3.2.1 8,9-epoxy-EPA increases cell viability of MDA-MB-231 grown in 0.5% FBS 
supplemented DMEM. 
The effect of 8,9-epoxy-EPA on MDA-MB-231 cell viability was evaluated in the presence of 
0.5% FBS supplemented DMEM. As shown in figure 3.3, an increase in cell viability (MTT 
assay) was observed for both 8,9-epoxy-EPA alone (10.0±2.0%, p=0.002) and in combination 
with DCU (16.0±1.6, p<0.0001). Cells that were treated with either DMSO or DCU alone did 
not exhibit altered cell proliferation and viability.  
 
Figure 3.3: Effect of 24 hr 8,9-epoxy-EPA treatment (10µM) alone and in combination with N,N’-
dicyclohexylurea (DCU) (10µM) on MDA-MB-231, cells cultured in 0.5% FBS supplemented DMEM. Cell 
viability was assessed using MTT assay. A: 8,9-epoxy-EPA increased cell viability significantly. * 10.0±2.0%, 
p=0.022. B: 8,9-epoxy-EPA in combination with DCU increased cell viability significantly. ** 16.0±1.6 versus 
DCU treated cells, p<0.0001. Data represent the mean ± SE, n=3 
Consistent with the finding from MTT assay cell viability was also increased when evaluated 
by trypan blue exclusion assay. As shown in figure 3.4, 8,9-epoxy-EPA alone appeared to 
increase cell viability with 60.9±43.6% (versus DMSO treated cells), and  in combination 
with DCU 15.9±13.1% (versus DCU treated cells). However, these data did not attain 
statistical significance because of the data variation.  
Although the data did not reach statistical significance, the trend is consistent with findings 































Figure 3.4: 8,9-epoxy-EPA alone and in combination with DCU increases viability of MDA-MB-231 cells. 
Viable cells were counted using trypan blue exclusion assay. 8,9-epoxy-EPA alone increases cell viability by 
60.9±43.6%. 8,9-epoxy-EPA + DCU increases cell viability by 15.9±13.1% over DCU treated cells. Controls 
were incubated with DMSO or DCU alone. Data represent mean ±SE from n=3 independent experiments.  
These results indicate that 8,9-epoxy-EPA might enhance cell proliferation and viability in 
MDA-MB-231 cells. The greater inter-assay variation in trypan blue exclusion data may have 
contributed to the lack of statistical significance. 
 
3.2.2 Effect of 8,9-epoxy-EPA on viability of serum starved MDA-MB-231 cells. 
We considered whether the effects of 8,9-epoxy-EPA on cell viability may be influenced by 
the presence of a growth stimulus (FBS). Thus, serum starved MDA-MB-231 cells were 
exposed to the same treatments as described above. No visible change in confluence or cell 
shape was found by studying the cells by microscope (figure 3.5). Live cells were again 
counted by trypan blue exclusion assay, and no change in cell proliferation and viability were 




Figure 3.5: The effect of 8,9-epoxy-EPA on serum starved MDA-MB-231 cells did not show any visible 



























Figure 3.6: Treatment with 8,9-epoxy-EPA alone and in combination with DCU did not influence MDA-MB-
231 cell viability when grown in serum free media. Data represent mean ±SE from n=3 independent 
experiments. 
 
3.3 Effect of 8,9-epoxy-EPA on cell cycle in MDA-MB-231 cells. 
The increased cell viability of MDA-MB-231 from MTT assay, when exposed to 8,9-epoxy-
EPA suggested that there may be an acceleration in the rate of the cell cycle. To investigate 
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this further, the cells were cultured in 0.5% FBS supplemented media, and exposed to the 
treatments described above. Table 3.1 show that no significant change was found in any of the 
cell cycle phases. 
 
Figure 3.7: Flow measurement of MDA-MB-231 cells treated with DMSO only (A), 8,9-epoxy-EPA (B), 8,9-
epoxy-EPA and DCU (C) and DCU alone (D). No difference in amount of cells in each phase of the cell cycle 











Table 3.1: Percentage of MDA-MB-231 cells in each cell cycle phase after treatment with 8,9-epoxy-EPA alone 
and in combination with DCU. No significant change was found. Data represent mean ±SE, n=3. 















3.4 Effect of 8,9-epoxy-EPA on expression of cell cycle regulatory proteins in MDA-MB-
231 cells 
Next, we investigated the effect of 8,9-epoxy-EPA on cell cycle regulatory protein expression. 
Cells were cultured in 0.5% FBS supplemented DMEM, and exposed to 8,9-epoxy-EPA 
alone. The expression of the cell cycle related proteins cyclin D1 cyclin E, Cdk 4 Cdk 6, and 
p21 were analyzed by Western blot analysis. To confirm equivalence of protein loading, β-
actin protein expression was also measured by immunoblotting of the same nitrocellulose 
filters that had been used for detection of cell cycle proteins. After 24 hr, a small, but non-
significant increase in expression of these proteins was found. Thus, p21 is 119.2±10.0%, 
cyclin D1 111.8±13.8%, cyclin E 112.0±14.2%, cdk4 118.3±21.1% and cdk6 119.3±12.2% 





Figure 3.8: Effect of 8,9-epoxy-EPA on expression of cell cycle regulatory proteins. MDA-MB-231 were treated 
with 8,9-epoxy-EPA for 24 hr and were harvested as described under materials and methods. Equal amounts of 
cell lysates were analyzed by Western blot analysis. Data represent mean protein expression/mean actin 
expression as percentage of control ±SE, n=3 independent experiments. 
 
 
3.5 Effect of 8,9-epoxy-EPA on MDA-MB-231 cells that had been exposed to the 
anticancer drug paclitaxel. 
8,9-epoxy-EPA increases cell viability of MDA-MB-231 breast cancer cells as shown above. 
To test the importance of the potential cytoprotective effect of the n-3 fatty acid epoxide, cells 




3.5.1 Effect of paclitaxel on viability of MDA-MB-231 cells  
The effects of different concentrations of paclitaxel on MDA-MB-231 cell viability are shown 
in figure 3.9. Cells were grown in 0.5% FBS supplemented DMEM, exposed to varying 
concentrations of paclitaxel for 24 hr and then analyzed by MTT assay. A reduction in the 
number of viable cells was found between 1-10nM paclitaxel (66.2±1.0% of control viability 













0.1nM 1nM 10nM 20nM 50nM
Paclitaxel concentration
 
Figure 3.9: Concentration-dependent effect of paclitaxel on the viability of MDA-MB-231 cells. At 0,1nM 
paclitaxel viable cells are 100.5±3.2% compared to DMSO treated cells, and 97.12±3.4% at 1nM. At 10nM cell 
viability is reduced to 66.2±1.0% of control, and 62.5±0.5% and 62.17±2.0% at 20nM and 50nM, respectively. 
Data represent mean ±SE, n=3 independent experiment. 
 
3.5.2 8,9-epoxy-EPA restore MDA-MB-231 viability in paclitaxel treated cells. 
Cells grown in 0.5% FBS supplemented DMEM were exposed to 2nM, 5nM or 10nM 
paclitaxel in addition to 8,9-epoxy-EPA (alone and in combination with DCU) for 24 hr. Cell 
viability was assessed by MTT assay.  As shown in figure 3.10, treatment with 8,9-epoxy-
EPA either alone or in combination with DCU, increased viability of MDA-MB-231 in cells 
that also received paclitaxel. Paclitaxel (2nM) did not decrease cell viability significantly 
compared to DMSO treated cells. However, the increase in cell viability in cells exposed to 
8,9-epoxy-EPA  (10.6±1.4%, p<0.0001 versus paclitaxel treated cells) and 8,9-epoxy-EPA + 
45 
 
DCU (9.3±0.5%, p<0.0001, versus paclitaxel+DCU treated cells) was significant in both 
cases. In contrast paclitaxel (5nM and 10nM) decreased cell viability to 89.0±2.3% (p=0.043) 
and 74.0±4.3% (p<0.0001) of respective controls. In the case of 5nM paclitaxel, the increase 
in viability of cells treated with 8,9-epoxy-EPA and 8,9-epoxy-EPA + DCU, was 31.8±4.6% 
(p<0.0001) compared to paclitaxel treated cells, and 30.5±4.2% (p<0.0001) compared to 
paclitaxel+DCU treated cells. For 10nM paclitaxel treatment the increase was 39.8±10.0% 
(p<0.0001) for 8,9-epoxy-EPA alone and 44.17±6.7 (p<0.0001) for 8,9-epoxy-EPA in 
combination with DCU. 
 
Figure 3.10: Effect of 2nM, 5nM and 10nM paclitaxel in combination with 8,9-epoxy-EPA and 8,9-epoxy-EPA 
+ DCU on viability of MDA-MB-231 cells. A: 8,9-epoxy-EPA alone and in combination with DCU increases 
cell viability significantly: *10.6±1.4%, p<0.0001 versus paclitaxel alone. **9.3±0.5%, p<0.0001 versus 
paclitaxel+DCU treated cells. B: 5nM paclitaxel in combination with 8,9-epoxy-EPA and 8,9-epoxy-EPA + 
DCU increases cell viability significantly. . * 31.8±4.6% p<0.0001 versus paclitaxel alone. ** 30.5±4.2%,, 
p<0.0001 versus paclitaxel+DCU treated cells. C: 10nM paclitaxel in combination with 8,9-epoxy-EPA and 8,9-





44.17±6.7, p<0.0001 versus paclitaxel+DCU treated cells. Data represent mean ±SE, n=3 independent 
experiments. 
 
3.5.3 Effect of combined treatment with 8,9-epoxy-EPA and paclitaxel on cell cycle 
kinetics in MDA-MB-231 cells  
To further investigate the increased viability observed when MDA-MB-231 cells were 
exposed to 8,9-epoxy-EPA in the presence of paclitaxel, cell cycle analysis by flow cytometry 
was carried out. The cells were exposed to 8,9-epoxy-EPA (10µM) alone and in combination 
with DCU (10µM) in the presence of 10nM paclitaxel for 6 and 24 hr. After 6 hr, a significant 
decrease of cells accumulated in G0/G1 phase was observed compared to cells treated with 
DMSO and cells treated with paclitaxel alone.  No related increase in cell accumulation was 
found in any of the other phases. At 24 hr the same significant decrease of cells in phase 
G0/G1 phase were found. At this timepoint there also was a related accumulation of cells in 
G2/M phase. 
Only one significant difference between 8,9-epoxy-EPA treated cells and control was found. 
In G0/G1 phase, cells treated with 8,9-epoxy-EPA in combination with paclitaxel decreased 
24.05±0.796% (p=0.0069) compared to cells treated with only paclitaxel for 24 hr. Because 
cell viability experiments have shown that 8,9-epoxy-EPA restore the viability of MDA-MB-
231 treated with paclitaxel, the same effect was expected to be found in cell cycle 
experiments. The reversal of paclitaxel effect in cell cycle would result in an increased 
amount of cells in G0/G1 phase. Thus, the significant decrease is not as expected.    
No other significant differences was fount between MDA-MB-231 cells treated with 8,9-
epoxy-EPA in combination with paclitaxel compared to control. Thus, 8,9-epoxy-EPA did not 
significantly alter the effect of paclitaxel on cell cycle. 
  
 
Figure 3.11: Flow cytomerty of MDA-MB-231 cells after 6 hr treatment of DMSO only (A), paclitaxel (B), 




Figure 3.12: Flow cytomerty of MDA-MB-231 cells after 24 hr treatment of DMSO only (A), paclitaxel (B), 















Table 3.2: Percentage of MDA-MB-231 cells in each cell cycle phase after treatment with 8,9-epoxy-EPA alone 
or in combination with DCU in the presence of paclitaxel after 6 hr. *Accumulation of cells in phase G0/G1 








52.88±0.07 17.18±1.31 24.56±1.66 
Paclitaxel 48.67±1.70* 16.82±1.74 28.04±1.13 
Paclitaxel + 
8,9-epoxy-EPA 




46.11±0.56*** 19.37±1.58 28.04±1.23 
Paclitaxel + 
DCU 
47.25±1.05**** 17.25±0.93 28.68±0.35 
*p=0.015 compared to DMSO. ** p=0.0015 compared to DMSO. ***p=0.0008 compared to 













Table 3.3: Percentage of MDA-MB-231 cells in each cell cycle phase after treatment with 8,9-epoxy-EPA alone 
or in combination with DCU in the presence of paclitaxel after 24 hr. Accumulation of cells decreased 
68.4±1.55% (p<0.0001) in G0/G1 phase and increased 133.03±1.79% (p=<0.0001) in G2/M phase for paclitaxel 
compared to DMSO treated cells. 8,9-epoxy-EPA and paclitaxel treated cells decreased significantly compared 







56.30±1.17 13.13±0.15 23.49±0.73 
Paclitaxel 17.81±0.38a 10.52±0.69f 54.74±1.06g 
Paclitaxel + 
8,9-epoxy-EPA 




15.46±0.97c 11.34±0.62 55.43±2.14i 
Paclitaxel + 
DCU 
17.25±1.18d 10.77±1.10 55.06±1.20j 
a p<0.0001 compared to DMSO. b p<0.0001 compared to DMSO. c p<0.0001 compared to 
DMSO. d p<0.0001 compared to DMSO. e p=0.0069 compared to paclitaxel.f p=0.0306 
compared to DMSO.g p<0.0001 compared to DMSO. h p<0.0001 compared to DMSO. i 




































In this study we have investigated the effect of 8,9-epoxy-EPA in the human breast cancer 
cell line MDA-MB-231.  The cells were treated with 8,9-epoxy-EPA alone or in combination 
with the epoxide hydrolase inhibitor N,N’-dicyclohexylurea (DCU). Studies have shown that 
fatty acid epoxids are hydrolysed to diols by epoxide hydrolase [16]. DCU was therefore 
added to the treatment to ensure the epoxide was kept stable long enough to detect possible 
effects on cell proliferation. 
Studies have shown that EPA has anti-proliferative effects on breast cancer cells and other 
cancers [17, 18, 20, 21], but the mechanism is not fully understood. EPA is metabolized to 
several different eicosanoids in the body. 8,9-epoxy-EPA is one of these eicosanoids [13]. 
This compound is one of five monoepoxides formed when EPA is metabolized by cytochrome 
P450. No studies have previously been carried out in order to investigate the effect of epoxy-
EPAs on cancer growth, which can be relevant for understanding how n-3 fatty acids are 
beneficial in cancer.  
EPA is an analogue of arachidonic acid (AA). When AA is metabolized by CYP 450, 
epoxyeicosatrienoic acids (EETs), the monoepoxy forms of AA, are formed. Studies of EET 
on cancer cells have revealed a possible cancer growth stimulatory effect [30-32].  This effect 
may be related to protection of the cancer cells against apoptosis or control of angiogenesis 
[30-32] 
This study consists of two parts. In the first part we tested the actions of 8,9-epoxy-EPA on 
cell viability and the cell cycle. In the second part we tested the effects of 8,9-epoxy-EPA on 
cancer cell viability and cell cycle in the presence of paclitaxel, an established cytotoxic 
agent. Previous studies have suggested that n-3 fatty acids my increase the cytotoxic effect of 
cytotoxic agents [44, 45] 
 
4.1 Effect of 8,9-epoxy-EPA on MDA-MB-231 cell viability 
MDA-MB-231 cells were exposed to 8,9-epoxy-EPA alone and in combination with N,N’-
dicyclohexylurea (DCU) for 24 hr. The cell viability was assessed using MTT-assay and 
trypan blue counting. Based on studies showing an anti-proliferative effect of EPA on cancer 
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cells, we anticipated a possible decrease in MDA-MB-231 cell viability. In contrast to this, we 
found that the cell viability increased. The increase was consistent for both MTT-assay and 
trypan blue exclusion.   
The increase in cell viability was slightly greater in the case of the combination with DCU, 
which indicates that DCU may increase the effect of 8,9-epoxy-EPA by preventing its 
hydrolysis by the soluble epoxy hydrolase (sEH) enzyme. 
To test whether the potential confounding effect of growth factors on proliferation could be 
avoided, MDA-MB-231 cells were cultured in serum starved media and exposed to the same 
treatment as described above. No change in viability between cells treated with 8,9-epoxy-
EPA compared to control were found in this experiment. This suggests that growth 
stimulation by FBS appears to be required for the effect of 8,9-epoxy-EPA on cell 
proliferation to be expressed.  
Our results indicates a cytoprotective effect of 8,9-epoxy-EPA on MDA-MB-231 cells. Two 
different methods, MTT-assay and trypan blue counting, were used to show the same 
enhanced cell viability. Although the increased cell viability has not been anticipated based on 
the suggested anti-proliferative effect of EPA on cancer cells, it is consistent with previous 
reports of the effect of EET. EETs stimulate cyclin D1 expression, but 8,9-epoxy-EPA did not 
appear to exert a similar effect which would have been consistent with increased growth. 
However, EETs also increase viability by inhibiting apoptosis [31, 32]. Due to time constrains 
and the need to develop further new assays, this was not assessed in the present project. It is 
conceivable that 8,9-epoxy-EPA also inhibits cell death in MDA-MB-231. 
 
4.2 Effect of 8,9-epoxy-EPA on cell cycle 
The increased cell viability of MDA-MB-231 when exposed to 8,9-epoxy-EPA suggested that 
there may be an acceleration in the rate of the cell cycle. We exposed the cells to the same 
treatment as described earlier and measured cell cycle kinetics using flow cytometry. The 
results did not show any changes in cell cycle distribution between 8,9-epoxy-EPA treated 
cells and control.  
We also tested the effect of 8,9-epoxy-EPA on cell cycle regulatory proteins using western 
blot analysis. For this experiment, the cells were only treated with 8,9-epoxy-EPA alone and 
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not in combination with DCU. The results from the immunoblotting did not show any 
significant changes in the expression of cell cycle regulatory proteins. These findings are 
consistent with the results from viability assay, but are not consistent with recent findings 
from this laboratory in murine endothelial cells. It is possible that a cell- and species- specific 
difference in cell response to epoxy-EPA occurs. Further studies are now required to assess 
this possibility.  
 
4.3 8,9-epoxy-EPA restore MDA-MB-231 viability in paclitaxel treated cells 
In the second part of this study we investigated the importance of the potential cytoprotective 
effect of 8,9-epoxy-EPA found by the cell viability experiments. MDA-MB-231 cells were 
exposed to 8,9-epoxy-EPA in the presence of paclitaxel, an established cytotoxic agent.  
Three different paclitaxel concentrations (2nM, 5nM and 10nM) were tested together with a 
constant concentration of 8,9-epoxy-EPA (10µM) alone and in combination with DCU 
(10µM). Cell viability was assessed using MTT-assay. 
Paclitaxel at the two highest concentrations decreased cell viability. This was reversed when 
cells were treated with 8,9-epoxy-EPA in presence of paclitaxel.  
The possible cytoprotective effect of 8,9-epoxy-EPA observed in these experiments are 
consistent with the results from the first experiments on cell viability. The increase in MDA-
MB-231 viability occurs not only when cells are exposed to 8,9-epoxy-EPA alone, but also in 
the presence of paclitaxel. Again, this finding was in contrast with what had been expected 
from studies in endothelial cells [44, 45], but illustrates potential cell-specific effects of n-3 
fatty acid epoxides.  
 
4.4 Effect of combined treatment with 8,9-epoxy-EPA and paclitaxel on cell cycle 
kinetics in MDA-MB-231 cells. 
Further, we investigated whether the possible cytoprotective effect of 8,9-epoxy-EPA on 
MDA-MB-231 cells in the presence of paclitaxel would show changes in cell cycle kinetics. 
The cells were exposed to 8,9-epoxy-EPA, alone and in combination with DCU, in the 
presence of paclitaxel. The treatments were conducted for 6hr and 24hr, and cell cycle 
kinetics was measured using flow cytometry.  
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After 6 hr a significant decrease of cells in G0/G1 occurred with paclitaxel. After 24 hr the 
decrease in the proportion of paclitaxel treated cells in G0/G1 phase occurred but was much 
more pronounced. At this timepoint there also was a related significant increase of 
accumulation of the same cells in G2/M phase. Thus, fewer cells are entering the cell cycle 
after 24 hr of paclitaxel treatment. The cell cycle distribution measures cell proportions, rather 
than absolute numbering. Those cells still in the cell cycle are distributed preferentially in 
G2/M, suggesting that they are arrested in G2/M phase and do not progress to mitosis. Based 
on the cell viability experiments, we expected to see a reversion of the paclitaxel effect on the 
cells when they were exposed to 8,9-epoxy-EPA  in addition. This implied less accumulation 
of cells in G2/M phase. No such effect was observed or 8,9-epoxy-EPA alone or in 
combination with DCU. However, it is noteworthy that the proportions of cells in G0/G1 had 
decreased further, which suggests that even fewer were cycling than in the presence of 
paclitaxel. Considered together, the increase in viability produced by 8,9-epoxy-EPA in the 
presence of paclitaxel might have been due to an increase in quiescent cells, not in the cell 
cycle. 
Because there is so little published literature regarding the effect of epoxide n-3 fatty acids on 
both normal cells and cancer cells, it is difficult to find any data that can be used to compare 
the results from these experiments with.  
 
4.5 Summary 
In summary, we found that 8,9-epoxy-EPA increased cell viability of MDA-MB-231. These 
results are contrary to the present view on EPAs anti-proliferative effect on cancer cells. Most 
likely CYP 450-derived epoxides are less important than EPA itself or other metabolites in 
altering cell proliferation.  
The increased cell viability was again evident when cells were exposed to 8,9-epoxy-EPA in 
the presence of paclitaxel. This is consistent with our previous findings in the present cell line, 
but is not in accord with studies that have suggested that the combination of anticancer drugs 
and n-3 fatty acids offers advantages over one treatment alone.  
The positive effect of 8,9-epoxy-EPA on MDA-MB-231 cell viability may be due to a similar 
mechanism as the apoptosis inhibiting effect of EET. Further studies may therefore include 
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apoptosis studies of 8,9-epoxy-EPA treated MDA-MB-231 cells. Further studies also need to 
address the signaling mechanisms by which n-3 epoxides control cyclin D1 expression in 
murine endothelial cells. With this information it will eventually be possible to understand the 
emerging difference between cell types in response to the epoxides. This information is 
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6.1 Western blotting protocol 
Washing and lysis of cellpellets: 
• Resuspend cellpellet in 0.5 ml ice-cold PBS and transfer to 1.5 ml eppendorf tubes. 
• Add another 0.5 ml PBS to original tube to wash out cell rests, and transfer to the 
eppendorf tube. 
• Spin down at highest rpm for 5 min at 4⁰C. 
• Remove supernatant, flip the tube, and resuspend in 1 ml PBS. 
• Spin down again, and remove supernatant. 
Part A: 
PBS     25.96 ml 
1% Igepal    4 ml 
0.5% Sodium deoxycholate  10 ml 
0.1% SDS    0.2 ml 
Total     40 ml 
 
Lysis buffer = part A + phosphatase inhibitors 
 
Part A     4992.5 µl 
0.1 mM PMSF     2.5 µl 
5 µg/ml aprotinin   2.5 µl 
5 µg/ml leupeptin   2.5 µl 
Total     5 ml 
 
 
• Add lysis buffer to tubes (20 µl per one harvested well from 24-well plate).  
• Pipette up and down when adding lysis buffer without make bubbles, vortex and 
incubate on ice for 30-40 min. Vortex a few times during incubation. 
• Spin down at 10 000 g for 10 min at 4⁰C. The supernatant do now contain the proteins. 
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• Transfer 4 µl of the supernatant to a new tube, freeze the stock in -80⁰C (or remove all 
of supernatant to another new tube, freeze this and discard pellet). 
• Put the tubes with 4 µl protein on ice. 
 
BCA assay – quantification: 
• To tube containing 4 µl protein; add 66 µl water. (= 70 µl, dilution factor = 17.5) 
• Set up bovine serum albumin (BSA) standards as per table below using 2 mg/ml BSA 
and diluted lysis buffer (diluted 17.5 times). I.e.  400 µl lysis buffer + 6600 µl water = 
17.5 times diluted lysis buffer. 
BSA stock = 2 mg/ml X 1ml (from 1% BSA: 0.2 ml 1% BSA + 0.8 ml diluted buffer) 
Tube Diluted buffer, µl BSA stock, µl Final concentration, 
µl 
A 0 300 of BSA stock 2000 
B 125 375 of BSA stock 1500 
C 325 325 of BSA stock 100 
D 175 175 of B 750 
E 325 325 of C 500 
F 325 325 of E 250 
G 325 325 of F 125 
H 120 180 of G 75 
I 300 200 of G 50 
J 400 100 of G 25 
K 150 150 of J 12,5 
L 400 0 0 = Blank 
 
• Prepare BCA working solution in ratio 50A:1B. I.e. 40 ml A + 0.8 ml B. (Reagent A 
and B from BCA protein assay kit).  Vortex. 
• Add 25 µl of BSA standards and test samples to clear 96-well plate in duplicates. 
• Add 200 µl BCA working solution into each well using multi-channel pipette. 
• Shake on orbital shaker for 30 seconds. 
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• Seal plate with parafilm (to prevent water from enter the wells) and incubate at 37⁰C 
for 40 min. 
• Cool at room temperature for 30 minutes. 
• Read at 540 nm on plate reader. 
• If there is moist on the lid after reading, cool a little longer and do another reading. 
• If there is a big difference between the duplicates, also do a new reading. Make sure 
there are no bubbles in the wells. 
 
Making the gel: 
• Put together the gel cassette. For Mini-PROTEAN®3 Cell Assembly:  
o Place a short plate on top of a spacer plate.  
o Slide the two plates into the casting frame, keeping the shortplate facing the 
front. Insure both plates are flush at the bottom on a level surface. 
o Lock the pressure cams. 
o Tape the bottom of the glass plates to secure leaking. 
o Place the gel cassette assembly on the grey casting stand gasket with short 
plate facing you. (Use filter paper under and parafilm over gaskets for less 
leakage).  
• Prepare 12% separating gel. 
• Use a Pasteur pipette to apply the gel mix to the gel casting apparatus. Fill it up to the 
“green edge” (about 5 cm). If it starts leaking, keep adding more gel mix until it stops. 
• Place about 5 drops of BuOH evenly across the gel to exclude air during 
polymerization. 
• Allow the gel to set for 30-40 minutes. 
• Wash off BuOH with water 5 times. Remove water from gel carefully by putting a 
filter paper between the glass plates. 
 
• Prepare 5% stacking gel. 
• Place the stacking gel on top of the separating gel with a Pasteur pipette and insert the 
comb.  
• Allow to set for 30 minutes.           
66 
 
• Prepare test samples. Calculate how much sample is needed for the wanted 
concentration of protein beforehand. Add it to an equal amount of reducing buffer (in 
addition to water if necessary) in an eppendorf tube. Boil for 5 min (make hole in lid 
of tube with needle first!), and spin very short on a centrifuge.  
o Also prepare 1 x running buffer (electrophoresis buffer) from 5 x running 
buffer.   
o I.e. 100 ml 5 x running buffer + 400 ml deionized water. 
• When the gel is ready, remove comb and wash with water. Remove water in the wells 
with a syringe. 
• Remove gel cassette from the casting frame and place it into the electrode assembly 
with short plate facing inward.  
• Apply 5 µl of marker on one side and apply samples in each well. (An evenly amount 
of sample must be loaded). There have to be samples in each well in order to make the 
running work properly.  
• Slide the gel cassettes and electrode assembly into the clamping frame. Lower into the 
mini tank. Fill up with 1 x running buffer. Make sure it is very full in between the 
glass cassettes. 
• Run the gels at 200V (Power PAC 200) for about 2 hr for 1.5 mm gels, until the 
bromophenyl blue reaches the end of the gel.  
 
Transferring proteins from gel to nitrocellulose membrane: 













• Prepare stack by assembling the components in the following order (in tray with 
transfer buffer). Start at the bottom: 
TOP 
   Clear plastic holder 
   1 pad 
   3 x filter paper (soaked) 
   Nitrocellulose 
   Gel (remove excess gel on edges before stacking) 
   3 x filter paper (soaked) 
   1 pad 
   Black plastic folder 
   BOTTOM 
 
Do not touch the middle of the gel! Smoothen over the filter paper on top of the membrane to 
reduce bubbles. 
• Fasten folder and place into blotting module. Make sure the black side of the folder is 
facing the black side of the blotting module!  
• Place into tank and fill with transfer buffer.  
• Place tank in large esky surrounded by ice and fill ice container in tank with ice. Refill 
the ice in the ice container every 30 minutes. 
• Run at 100V (Power Pac 200) for 1.5 hr at least for 1.5 mm gels. 
• Put membrane between to filter papers and keep flat. 
 
Development of blot: 
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• Remove blot from filter paper and put into a box containing the dye ponceus C.  
• Shake on orbital shaker for 10 minutes. 
•  Wash quickly with water. 
• Scan to see protein bands and ensure efficiency of transfer.  
• Place membrane in box containing blocking milk solution. 
• Shake for 1 hr. 
• Move blot to new box with blocking milk solution and primary antibodies. 
• Incubate on shaker in cold room overnight, 4 ⁰C.  
• Place membrane in new box for washing. Wash 5 x 5 min and 5 x 2.5 min with ~20 ml 
(enough to cover the membrane and a little more) TBS/Tween on shaker. 
• Incubate in 10 ml blocking milk solution and secondary antibody for 1 hr on shaker. 
PROTECT FROM LIGHT IN THIS STEP AND FROM NOW ON! 
• Remove secondary antibody. 
• Wash blot with ~20 ml TBS/Tween for 5 x 5 min and 5 x 2.5 min, and then wash for 2 
x 5 min with TBS (NO TWEEN). 
• Dry blots between 2 filter papers. Wrap in foil to protect from light. 
• Scan with Odyssey. 
 
 
 
 
 
 
 
